These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19756916)

  • 1. The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.
    Kelleher MT; Fruhwirth G; Patel G; Ofo E; Festy F; Barber PR; Ameer-Beg SM; Vojnovic B; Gillett C; Coolen A; Kéri G; Ellis PA; Ng T
    Target Oncol; 2009 Sep; 4(3):235-52. PubMed ID: 19756916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.
    Weitsman G; Barber PR; Nguyen LK; Lawler K; Patel G; Woodman N; Kelleher MT; Pinder SE; Rowley M; Ellis PA; Purushotham AD; Coolen AC; Kholodenko BN; Vojnovic B; Gillett C; Ng T
    Oncotarget; 2016 Aug; 7(32):51012-51026. PubMed ID: 27618787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
    Shukla HD; Mahmood J; Vujaskovic Z
    Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics as a guiding tool for more effective personalized therapy.
    Lee JM; Kohn EC
    Ann Oncol; 2010 Oct; 21 Suppl 7(Suppl 7):vii205-10. PubMed ID: 20943616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
    Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making the most of pathological specimens: molecular diagnosis in formalin-fixed, paraffin embedded tissue.
    Fairley JA; Gilmour K; Walsh K
    Curr Drug Targets; 2012 Nov; 13(12):1475-87. PubMed ID: 22974391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of individual response to anticancer therapy: historical and future perspectives.
    Unger FT; Witte I; David KA
    Cell Mol Life Sci; 2015 Feb; 72(4):729-57. PubMed ID: 25387856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systems approach to clinical oncology: focus on breast cancer.
    Abramovitz M; Leyland-Jones B
    Proteome Sci; 2006 Apr; 4():5. PubMed ID: 16595007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLIM-FRET for Cancer Applications.
    Rajoria S; Zhao L; Intes X; Barroso M
    Curr Mol Imaging; 2014; 3(2):144-161. PubMed ID: 26023359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional proteomic biomarkers in cancer.
    Larijani B; Perani M; Alburai'si K; Parker PJ
    Ann N Y Acad Sci; 2015 Jun; 1346(1):1-6. PubMed ID: 25801208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic identification of Reticulocalbin 1 as potential tumor marker in renal cell carcinoma.
    Giribaldi G; Barbero G; Mandili G; Daniele L; Khadjavi A; Notarpietro A; Ulliers D; Prato M; Minero VG; Battaglia A; Allasia M; Bosio A; Sapino A; Gontero P; Frea B; Fontana D; Destefanis P
    J Proteomics; 2013 Oct; 91():385-92. PubMed ID: 23916412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues.
    Berg D; Hipp S; Malinowsky K; Böllner C; Becker KF
    Eur J Cancer; 2010 Jan; 46(1):47-55. PubMed ID: 19914823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of oncoproteomics to cancer biomarker discovery.
    Cho WC
    Mol Cancer; 2007 Apr; 6():25. PubMed ID: 17407558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics in cancer research: Are we ready for clinical practice?
    Maes E; Mertens I; Valkenborg D; Pauwels P; Rolfo C; Baggerman G
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):437-48. PubMed ID: 26277237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.
    Kamel HFM; Al-Amodi HSAB
    Genomics Proteomics Bioinformatics; 2017 Aug; 15(4):220-235. PubMed ID: 28813639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards defining biomarkers indicating resistances to targeted therapies.
    Stehle F; Schulz K; Seliger B
    Biochim Biophys Acta; 2014 May; 1844(5):909-16. PubMed ID: 24269379
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.